Clinical Trial 46528

Brooklyn, NY 11235


A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab
Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's
Disease Who Have Failed Anti-TNF therapy

You may qualify to participate if you meet the following requirements:
• 18 to 80 years of age
• Diagnosed with Crohn’s disease for at least 3 months
• Currently have Crohn’s disease symptoms
• Have found that at least one Crohn’s medication, referred to as a biologic agent, doesn’t work well for you.

Qualified Participants May Receive:

Screening (V1): $150
Baseline (V2): $150
Week 4 (V3): $150
Week 8 (V4): $150
Week 12 (V5): $150
Week 16 (V6): $150
Week 20 (V7): $150
Week 24 (V8): $150
Week 28 (V9): $150
Week 32 (V10): $150
Week 36 (V11): $150
Week 40 (V12): $150
Week 44 (V13): $150
Week 48 (V14): $150
140 Day Follow up (Visit 15): $150
Unscheduled Visit: $150
Colonoscopy Procedure each occurrence: $250

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.